Recent 8-K filings for VKTX

• April 29, 2026, 7:59 PM ET earnings materiality 0.90 neutral item 2.02item 9.01 ◈ Earnings Releases

  Viking Therapeutics Reports Q1 2026 Net Loss of $158.3M, Cash of $603M; Phase 3 Obesity Trials Fully Enrolled

  Phase 3 VANQUISH-1 and VANQUISH-2 trials of subcutaneous VK2735 for obesity are fully enrolled; Phase 2 VENTURE study showed up to 14.7% weight loss at 13 weeks.

• February 11, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Vikings Q4 net loss $157.7M; cash $706M; oral VK2735 Phase 3 to start 3Q26

  Full-year 2025 net loss $358.5M ($3.19/sh) vs $110.0M in 2024; R&D spend $345M (up 240% YoY).

• October 22, 2025, 7:59 PM ET earnings materiality 0.80 neutral item 2.02item 9.01

  Viking Therapeutics Reports Q3 2025 Results, Cash $715M, VK2735 Phase 3 Trials On Track

  Q3 2025 net loss $90.8M ($0.81/share) vs $24.9M in Q3 2024; R&D expenses rose to $90.0M from $22.8M.

• August 19, 2025, 7:59 PM ET other material materiality 0.90 positive item 7.01item 9.01

  VK2735 oral tablet achieves up to 12.2% weight loss in Phase 2 obesity trial

  Mean weight loss up to 12.2% (26.6 lbs) from baseline at 13 weeks; placebo-adjusted up to 10.9% (p<0.0001).

• July 23, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Viking Therapeutics Q2 net loss $65.6M; Phase 3 VANQUISH obesity trial underway

  Net loss $65.6M ($0.58/share) vs $22.3M ($0.20) in Q2 2024; R&D spend $60.2M vs $23.8M.

• April 23, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Viking Q1 net loss $45.6M ($0.41/sh); cash $852M; VK2735 Phase 3 expected 2Q25

  Net loss of $45.6M ($0.41 per share) vs $27.4M ($0.26) in Q1 2024; R&D expense rose to $41.4M.

• March 11, 2025, 7:59 PM ET other material materiality 0.85 positive item 1.01item 2.03item 8.01item 9.01

  Viking signs $150M manufacturing deal with CordenPharma for VK2735 supply

  Viking prepays $150M over 2025-2028 for dedicated API and fill/finish capacity for obesity drug VK2735.

• February 5, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Viking Therapeutics reports FY2024 net loss $110M; cash $903M; Phase 3 VK2735 planned 2Q25

  Net loss $110.0M ($1.01 per share) for FY2024, compared to net loss $85.9M ($0.91 per share) in 2023.

• November 4, 2024, 6:59 PM ET other material materiality 0.80 positive item 7.01item 9.01

  VK2735 oral Phase 1 shows up to 8.2% weight loss; Phase 2 data support monthly maintenance dosing

  Oral VK2735 achieved up to 8.2% mean weight loss from baseline (6.8% placebo-adjusted) at 28 days.

• October 23, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Viking Therapeutics Q3 net loss $24.9M; cash $930M; pipeline advances with VK2735 and VK2809

  Net loss of $24.9M ($0.22 per share) vs $22.5M loss in Q3 2023; R&D expense $22.8M.

• July 24, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Viking advances VK2735 to Phase 3 for obesity; Q2 net loss $22.3M

  VK2735 to advance to Phase 3 after positive VENTURE study; End-of-Phase 2 meeting with FDA planned for 2H24.

• June 4, 2024, 7:59 PM ET other material materiality 0.90 positive item 7.01item 9.01

  Viking Therapeutics positive Phase 2b VOYAGE data: up to 75% NASH resolution with VK2809 vs 29% placebo (p=0.0001)

  NASH resolution with no worsening of fibrosis: 63-75% for VK2809 groups vs 29% placebo (p<0.05 for each, combined p<0.0001).

• April 24, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01 ◈ Earnings Releases

  Viking Q1 net loss $27.4M; VK2735 obesity drug shows up to 14.7% weight loss; cash $963M

  Q1 net loss $27.4M ($0.26/sh), R&D expense $24.1M, G&A $10.0M.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.75 · Most common event earnings

9 positive 0 negative 8 neutral

source · VKTX on sec.gov